



## **Eurofins announces the success of the partial refinancing of its 2022 Schuldschein loans via a new Schuldschein issuance**

**15 October 2020**

Eurofins Scientific S.E. ("**Eurofins**"), a global leader in bioanalytical testing, announces that it has successfully issued a new EUR 350m Schuldschein loan (the "**New SSD**") offering a blended interest rate of 1.78%\* with an average maturity of 7.8 years.

Demand was strong (the order book totals more than 2.2x the final size of the issuance), with more than 60 investors willing to participate. The New SSD is structured in tranches of 5, 7 and 10 years, with both fixed and floating interest rates, with more than 85% of the transaction on the 7- and 10-year tenors.

Purpose of the New SSD is essentially to refinance the Schuldschein loans that are maturing in July 2022: out of the EUR 363.5m outstanding 2022 Schuldschein loans, EUR 318m are going to be repaid between today and January 2021 thanks to the proceeds of the New SSD. Through this refinancing exercise, Eurofins is extending the average life of its senior debt instruments from 3.3 years to 4.1 years.

BayernLB, Credit Agricole CIB, HSBC and Natixis acted as joint arrangers and HSBC is acting as the loan agent for the transaction.

*\*Calculated at current market values of the Euribor (floored)*

### **Notes to Editors:**

**For more information, please visit [www.eurofins.com](http://www.eurofins.com) or contact:**

Investor Relations  
Eurofins Scientific SE  
Phone: +32 2 766 1620  
E-mail: [ir@eurofins.com](mailto:ir@eurofins.com)

### **About Eurofins – the global leader in bio-analysis**

Eurofins Scientific, through its subsidiaries (hereinafter "Eurofins" or "the Group"), believes it is the global leader in food, environmental, pharmaceutical and cosmetics products testing and in agrosience CRO services. It is also one of the global independent market leaders in certain testing and laboratory services for genomics, discovery pharmacology, forensics, CDMO, advanced material sciences and in the support of clinical studies. In addition, Eurofins is one of the leading global emerging players in esoteric and molecular clinical diagnostic testing. With over **48,000 staff** across a network of more than 900 independent companies in over **50 countries** generally specialised by end client markets and operating more than **800 laboratories**, Eurofins offers a portfolio of over **200,000 analytical methods** to evaluate the safety, identity, composition, authenticity, origin, traceability and purity of a wide range of products, as well as providing innovative clinical diagnostic testing services. The Group's objective is to provide its customers with high-quality and innovative services, accurate results on time and, when requested, expert advice by its highly-qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and a very large range of testing methods.

As one of the most innovative and quality-oriented international groups in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the increasing demands of regulatory authorities and healthcare practitioners around the world.

Shares in Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

*Until it has been lawfully made public widely by Eurofins through approved distribution channels, this document contains inside information for the purpose of Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse, as amended.*

### **Important disclaimer:**

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific's management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company's management as of the date of publication, but no guarantees can be made as to their completeness or validity.